FindMyKOL

Kristi McIntyre, MD

Basic profile

Texas Health Dallas

ORCIDOn fileNPIOn fileSign in to see identifiers
✓ Itemized record
RegionDallas, TX · South CentralSpecialtyMedical OncologyFocusOncology
Active KOLFindMyKOL type: RegionalLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Kristi McIntyre is an Oncology physician affiliated with Texas Health Dallas. OpenAlex indexes 64 publications with 6,612 citations (h-index 25); ClinicalTrials.gov lists 1 registered study matched to this name.

Overview

Scholarship

indexed output and impact (OpenAlex)
64publications

Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.

6,612citations

Citations across these publications.

25h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
1clinical trials

Investigator role on registered studies.

View trials ↓
34companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓

Clinical trials

Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.

Industry payments

34 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • AstraZeneca
    Program year20253 paymentsResearch
    $990,994
  • Merck & Co.
    Program year20254 paymentsResearch
    $148,240
  • Tolmar
    Program year202516 paymentsResearch
    $72,622
All 124 payment records: search, sort and filter.Explore →

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    46.1%
    PD-1 inhibitor23.9%
    Pembrolizumab100%
    Part B, office-administered≥22 patients
    Platinum-based Drug14.7%
    Oxaliplatin98%Carboplatin2%
    Part B, office-administered≥17 patients

    + 7 more classes in this area

  • Blood & clotting

    25.3%
    Parenteral Iron Replacement13%
    Iron sucrose100%
    Part B, office-administered≥26 patients
    Erythropoiesis-stimulating Agent12.2%
    Darbepoetin alfa100%
    Part B, office-administered≥19 patients

    + 2 more classes in this area

  • Metabolism & gastrointestinal

    21.7%
    Other antiemetics18.8%
    Fosaprepitant100%
    Part B, office-administered≥39 patients
    Serotonin-3 Receptor Antagonist2.7%
    Palonosetron hcl56%Granisetron hydrochloride42%Ondansetron Odt1%Ondansetron Hcl1%
    Part D + Part B<11 patients

    + 3 more classes in this area

Where care is delivered (Part B)0.1% facility · 99.9% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”